← All trials
NCT03511391
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 9, 2018
- Primary completion
- Feb 14, 2022
- Completion date
- Aug 14, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 97
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ghent UniversityLead sponsor
- GZA Ziekenhuizen Campus Sint-AugustinusCollaborator
- Ghent UniversityOverall official - principal investigator
- AZ Sint-LucasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.